Island Pharmaceuticals doses first cohort in ISLA-101 study

Latest News

Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has dosed the first cohort in its single ascending dose study for ISLA-101.

ISLA-101 is a well-known drug candidate that is being repurposed to prevent and treat dengue and other mosquito- (or vector) borne diseases.

The study is being conducted by a contract research organisation, Beyond Drug Development, at Scientia Clinical Research’s clinical trial facilities in Sydney.

Island Pharmaceuticals said the study results are expected in early 2024. It said the insights gained will pave the way for optimising protocols for its planned Phase 2a PEACH clinical trial.

CEO Dr David Foster said, “We are delighted to see the start of this study with the dosing of our first subject. This news represents a critical step in our journey towards our PEACH clinical trial, and progressing ISLA-101 toward approval as a much-needed treatment for dengue fever and other mosquito-borne diseases.”